Trial Profile
A trial of SRA-737 in combination with immuno-oncology agents
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 17 May 2018
Price :
$35
*
At a glance
- Drugs SRA 737 (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 17 May 2018 New trial record
- 10 May 2018 According to a Sierra Oncology media release, the company is currently designing a clinical study evaluating SRA737 in combination with immuno-oncology agents, which potentially could be submitted to regulatory authorities in the fourth quarter of 2018.